Akero Therapeutics (NASDAQ:AKRO – Get Rating) released its quarterly earnings results on Friday. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.06, MarketWatch Earnings reports.
AKRO stock traded down $0.17 during midday trading on Friday, reaching $11.16. The stock had a trading volume of 228,747 shares, compared to its average volume of 193,980. The business has a fifty day simple moving average of $13.50 and a two-hundred day simple moving average of $18.34. The firm has a market cap of $390.82 million, a price-to-earnings ratio of -3.86 and a beta of 0.77. Akero Therapeutics has a twelve month low of $10.05 and a twelve month high of $30.53.
In related news, CEO Andrew Cheng sold 10,000 shares of Akero Therapeutics stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $17.59, for a total value of $175,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.09% of the stock is owned by company insiders.
Separately, Zacks Investment Research raised Akero Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Monday, May 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $38.40.
Akero Therapeutics Company Profile (Get Rating)
Akero Therapeutics, Inc, a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
- Get a free copy of the StockNews.com research report on Akero Therapeutics (AKRO)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.